Madras HC notice to Centre on plea to declare Covishield vaccine as unsafe

The petitioner, 41-year old Asif Riaz, also sought an interim injunction restraining the Central government and the Drugs Controller General of India from continuing with administering Covishield

Covishield
Press Trust of India Chennai
2 min read Last Updated : Feb 19 2021 | 9:36 PM IST

The Madras High Court on Friday

issued notice to the Centre and others, including Serum Institute of India, on a plea from a man who alleged serious side effects after being administered the Covishield vaccine last year during trial.

In his plea, which came up before Justice Abdul Quddhose, the petitioner sought a declaration that the traumatic health issues he faced following vaccination was a 'serious adverse event' as defined in the New Drugs and Clinical Trial Rules (NDCTR), 2019.

The Covishield vaccine should hence be declared 'not safe' he pleaded and also sought a direction to the SII to provide him a compensation of Rs five crore.

The petitioner, 41-year old Asif Riaz, also sought an interim injunction restraining the Central government and the Drugs Controller General of India from continuing with administering Covishield vaccine, pending disposal of his petition.

According to him, he volunteered in the phase-III trial of the vaccine and he was inoculated on October 1 last year at Sri Ramachandra Institute of Higher Education and Research here.

He experienced severe trauma due to acute neuro encephalopathy, a severe neurological disorder from October 11 to 26 and this was a serious adverse event as defined in NDCTR.

To his legal notice seeking compensation,SII replied last December that his condition was not related to the trial vaccine and the firm offered no proof to support such a view, he said.

The Director General of the Indian Council of Medical Research, in reply to his legal notice, merely stated that any serious event is compensated as per the NDCTR.

Despite request, he received no reply from the Drugs Controller of India on the report of an independent committee it appointed, which said the adverse event he went through had no link to the vaccine.

This panel neither heard him nor physically examined him before submitting its report, he said and sought constitution of an expert committee to go into records and give its view.

The petitioner said he has "...no end in sight for complete recovery," from the side effects following the vaccination.

The court ordered notice to the Union Health Secretary, DCGI, Director General of ICMR, and CEO of SII and chief of the Sri Ramachandra's ethics panel.

The matter has been posted for March 26.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Madras High CourtCoronavirus VaccineBharat BiotechSerum Institute

First Published: Feb 19 2021 | 9:30 PM IST

Next Story